Pfizer (PFE)
(Delayed Data from NYSE)
$29.22 USD
-0.05 (-0.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.22 USD
-0.05 (-0.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Zacks News
Trump Tweet on Drug Pricing Hits Biotech and Pharma ETFs
by Sweta Killa
President Donald Trump March 7 tweet on increasing competition and lowering drug prices sent fresh shockwaves across the industry.
J2 Global, eHealth, Pfizer, Amgen and Mylan highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
J2 Global, eHealth, Pfizer, Amgen and Mylan highlighted as Zacks Bull and Bear of the Day
Stock Market Roundup, March 7: SNAP Falls Again, Drug Stocks Dip
by Ryan McQueeney
Stocks opened in the red and were down slightly throughout the day on Tuesday. The healthcare sector witnessed some volatility after the release of the Republican plan to replace Obamacare and shares of Snap Inc. fell another 11% just days after its highly-anticipated IPO.
Trump's Tweet Hits Pharma Stocks, Promises Decreased Drug Prices
by Parth Panchal
A President Donald Trump tweet promising to increase competition and decrease prices in the drug industry sent pharmaceutical stocks falling on Tuesday.
Vertex to Buy Concert's Cystic Fibrosis Candidate for $160M
by Zacks Equity Research
Vertex Pharmaceuticals Incorporated (VRTX) announced a definitive deal to buy Concert Pharmaceuticals' (CNCE) cystic fibrosis (CF) pipeline candidate, CTP-656 for an upfront payment of $160 million in cash.
Trump Tweets, Drug Stocks Tank
by Mark Vickery
???Pricing for the American people will come way down!??? That???s not the only thing: shares of Pfizer (PFE) and Novartis (NOV) fell immediately.
What's in Store for Merck KGaA (MKGAF) in Q4 Earnings?
by Zacks Equity Research
Merck KGaA (MKGAF) is scheduled to report fourth-quarter 2016 earnings results on Mar 9.
by Zacks Equity Research
Dow 30 Stock Roundup: Wal-Mart, Home Depot Beat on Earnings, Boeing Wins $1.32B Order from Juneyao
by Swarup Gupta
The Dow notched up a record streak of gains over a holiday shortened week.
Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, Novartis Drugs
by Arpita Dutt
Cancer drugs developed by Pfizer (PFE) and Novartis got priority review while Bristol-Myers is being considered the next acquisition target.
Clovis (CLVS) Q4 Loss Wider than Expected; Focus on Rubraca
by Zacks Equity Research
Clovis Oncology, Inc. (CLVS) reported fourth-quarter 2016 loss of $1.83 per share, wider than the Zacks Consensus Estimate of a loss of $1.65.
Pfizer's Leukemia Candidate Gets Priority Review in U.S.
by Zacks Equity Research
Pfizer Inc. (PFE) announced that its Biologics License Application (BLA) for leukemia candidate inotuzumab ozogamicin has been accepted for priority review by the FDA.
Pfizer's Xeljanz Combo Comparable to AbbVie's Humira
by Zacks Equity Research
Pfizer, Inc. (PFE) announced top-line results from a head-to-head study comparing its rheumatoid arthritis (RA) drug Xeljanz with AbbVie, Inc.'s (ABBV) Humira.
Merck (MRK) Halts Late Stage Alzheimer Study; Shares Slip
by Zacks Equity Research
Merck & Co., Inc. (MRK) announced that it is discontinuing a late-stage study evaluating its pipeline candidate, verubecestat for the treatment of mild-to-moderate Alzheimer's disease due to lack of efficacy.
The Zacks Analyst Blog Highlights: Boeing, Pfizer, Goldman Sachs, NVIDIA and Twitter
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Boeing, Pfizer, Goldman Sachs, NVIDIA and Twitter
Allergan To Acquire ZELTIQ in $2.47 Billion Deal, ZELTIQ Shares Pop 13%
by Parth Panchal
Pharmaceutical giant Allergan (AGN) announced on Monday they will acquire ZELTIQ Aesthetics (ZLTQ) in a $2.47 billion deal.
Drug Stocks Earnings Slated for Feb 14: INCY, PRTA & More
by Zacks Equity Research
The year 2017 seems to have started on a positive note for investors in the U.S. Approximately 71.6% of the companies (or 358 members) in the S&P 500 Index have reported results so far.
Q4 Scorecard & Analyst Reports for Pfizer, Boeing & Goldman Sachs
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Boeing (BA), Pfizer (PFE) and Goldman Sachs (GS).
Model N (MODN) Q1 Loss Narrower than Expected, Guides Well
by Zacks Equity Research
Model N, Inc. (MODN) reported a loss (excluding stock based compensation) of 21 cents per share in first-quarter 2017, which was narrower than the Zacks Consensus Estimate.
ARIAD Files for EU Approval of Lung Cancer Drug Brigatinib
by Zacks Equity Research
ARIAD Pharmaceuticals, Inc. (ARIA) announced the submission of a Marketing Authorisation Application (MAA) for its experimental ALK inhibitor, brigatinib, with the European Medicines Agency (EMA).
Agilent (A) Announces Expanded Use of Diagnostic Assay (revised)
by Zacks Equity Research
Agilent Technologies (A) recently announced the expanded use of its diagnostic assay, Dako PD-L1 IHC 22C3 pharmDx.
Q4 Earnings Faring Well for Pharma ETFs
by Sweta Killa
Despite the fact that the industry primes posted mixed results, the stocks witnessed smooth trading following their results.
Drug Stocks Reporting Earnings on Feb 7: GILD, MNK & More
by Zacks Equity Research
Earnings growth turned positive in the last quarter and things are surely looking up as we stand in the middle of the earnings season.
Portola, HealthCare Royalty Partners Ink $150 Million Deal
by Zacks Equity Research
Portola (PTLA) announced that it has signed a royalty agreement with HealthCare Royalty Partners (HCR) for $150 million.
Merck???s Keytruda Gets Priority Review for Bladder Cancer
by Zacks Equity Research
Merck & Co., Inc.???s (MRK) two supplemental Biologics License Applications (sBLA) for its anti-PD-1 therapy, Keytruda, have been accepted under priority review by the FDA.